SUN-523 XLH Outcome Data from One Centre Experience with Burosumab

X-linked hypophosphataemia (XLH) is a rare, genetic, chronically debilitating and deformative bone disease that profoundly impacts the affected individual’s day-to-day functioning and quality of life. High levels of circulating fibroblast growth factor 23 (FGF23) lead to excess urinary phosphate exc...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Endocr Soc
Main Authors: Cheung, Moira, Sakka, Sophia, Gilbey-Cross, Robyn, Harries, Mark, Mathieson, Leigh
Format: Artigo
Jezik:Inglês
Izdano: Endocrine Society 2019
Teme:
Bone and Mineral Metabolism
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553073/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-523
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki